- Home
- ITRM vs DXR Comparison
ITRM vs DXR Comparison
Compare ITRM & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- DXR
- Stock Information
- Founded
- ITRM 2015
- DXR 1970
- Country
- ITRM Ireland
- DXR United States
- Employees
- ITRM N/A
- DXR N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- ITRM Health Care
- DXR Health Care
- Exchange
- ITRM Nasdaq
- DXR Nasdaq
- Market Cap
- ITRM 40.0M
- DXR 46.1M
- IPO Year
- ITRM 2018
- DXR N/A
- Fundamental
- Price
- ITRM $0.82
- DXR $10.00
- Analyst Decision
- ITRM Strong Buy
- DXR Strong Buy
- Analyst Count
- ITRM 2
- DXR 1
- Target Price
- ITRM $7.00
- DXR $25.00
- AVG Volume (30 Days)
- ITRM 751.2K
- DXR 3.5K
- Earning Date
- ITRM 08-13-2025
- DXR 01-01-0001
- Dividend Yield
- ITRM N/A
- DXR N/A
- EPS Growth
- ITRM N/A
- DXR 86.16
- EPS
- ITRM N/A
- DXR 0.11
- Revenue
- ITRM N/A
- DXR $119,714.00
- Revenue This Year
- ITRM N/A
- DXR N/A
- Revenue Next Year
- ITRM $270.19
- DXR N/A
- P/E Ratio
- ITRM N/A
- DXR $88.59
- Revenue Growth
- ITRM N/A
- DXR N/A
- 52 Week Low
- ITRM $0.81
- DXR $6.55
- 52 Week High
- ITRM $3.02
- DXR $10.00
- Technical
- Relative Strength Index (RSI)
- ITRM 35.21
- DXR 63.41
- Support Level
- ITRM $0.81
- DXR $9.05
- Resistance Level
- ITRM $0.90
- DXR $9.90
- Average True Range (ATR)
- ITRM 0.08
- DXR 0.26
- MACD
- ITRM -0.02
- DXR -0.01
- Stochastic Oscillator
- ITRM 4.46
- DXR 100.00
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.